Literature DB >> 16237476

Preclinical science regarding cannabinoids as analgesics: an overview.

M E Lynch1.   

Abstract

Modern pharmacology of cannabinoids began in 1964 with the isolation and partial synthesis of delta-9-tetrahydrocannabinol, the main psycho-active agent in herbal cannabis. Since then, potent antinociceptive and antihyperalgesic effects of cannabinoid agonists in animal models of acute and chronic pain; the presence of cannabinoid receptors in pain-processing areas of the brain, spinal cord and periphery; and evidence supporting endogenous modulation of pain systems by cannabinoids has provided support that cannabinoids exhibit significant potential as analgesics. The present article presents an overview of the preclinical science.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237476     DOI: 10.1155/2005/169093

Source DB:  PubMed          Journal:  Pain Res Manag        ISSN: 1203-6765            Impact factor:   3.037


  5 in total

Review 1.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

Review 2.  Neuromodulators for pain management in rheumatoid arthritis.

Authors:  Bethan L Richards; Samuel L Whittle; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

Review 3.  The emerging role of cannabinoid neuromodulators in symptom management.

Authors:  Mellar Davis; Vincent Maida; Paul Daeninck; Joseph Pergolizzi
Journal:  Support Care Cancer       Date:  2006-12-01       Impact factor: 3.359

Review 4.  Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies.

Authors:  Natasha Irrera; Alessandra Bitto; Emanuela Sant'Antonio; Rita Lauro; Caterina Musolino; Alessandro Allegra
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

5.  A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Authors:  Mark A Ware; Paul Daeninck; Vincent Maida
Journal:  Ther Clin Risk Manag       Date:  2008-02       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.